執行役員人事 2024年6月3日付June 3rd, 2024.
Announcements of company executives' personnel changes:
Santen Pharmaceutical Co., Ltd. (Headquarters: Osaka) announces personnel changes for June 3, 2024.
Mr. Sean Shoan has been appointed as Executive Officer, Head of China Business.
Record
Executive Officer Personnel Changes, effective June 3, 2024
| Name | New Position |
|---|---|
| Sean Shoan | Executive Officer Head of China Business |
| Name | New Position | Current Position |
|---|---|---|
| Rie Nakajima | Executive Officer, Chief Operating Officer, and Head of China Business |
Sean Shoan Biography:
Mr. Shoan joined Santen in 2024 and was appointed Executive Officer, Head of China Business.
As the head of Santen's business in China, he will be responsible for developing management and sales strategies, portfolio management, and commercial excellence in the region.In addition to extensive experience in business consulting and the pharmaceutical and healthcare industries, he brings extensive experience in China to further enhance the company's growth and development in the region and improve corporate value. He previously worked on projects for various companies, including pharmaceutical and medical equipment companies while working at McKinsey & Company. He then served as Director of Global Pharmaceutical Strategy at Novartis Global Headquarters in Switzerland in 2011 and franchise head of respiratory and osteoporosis business in China since 2012.He became the general manager of the diabetes area of Abbott in China and emerging markets in Asia in 2016 and was responsible for business expansion including new product launches. Recently, he led the strategy in RareStone Group as CEO, leading to early approval and market entry of pharmaceuticals and the development of a rare disease ecosystem.
Mr. Shoan obtained a Bachelor's degree in Engineering from Peking University and a Ph.D. in Engineering from Yale University.
About Santen
About Santen.
As a specialty company specializing in ophthalmology, Santen aims to contribute to the realization of people's "Happiness with Vision" by providing valuable products and services to patients, consumers, and healthcare professionals around the world. Since its founding, under the basic principle of "participating in the will of heaven," Santen has pursued the maintenance and improvement of eye health for more than 130 years. Currently, we are globally developing research and development, manufacturing, sales, and marketing activities in the ophthalmic field, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Our mission is to provide important value that has not been provided in the prevention, diagnosis, and treatment of eye diseases to patients and society through products and services created from expertise and patient perspectives in the ophthalmic field. We strive to create a future where as many patients as possible can lead happy and prosperous lives through realizing happiness through "seeing," and we are making every effort to realize a society where people around the world can feel this happiness.
For more information, please visit our website https://www.santen.com/ja.Please refer to https://www.santen.com/ja for this matter.Please refer to it.
Inquiries regarding this matter:
Santen Pharmaceutical Co. Corporate Communication
Email: communication@santen.com
